A Phase I Study of IRX4204 in Combination With Erlotinib in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Latest Information Update: 08 Apr 2024
At a glance
- Drugs IRX 4204 (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Io Therapeutics
- 02 Apr 2024 Planned End Date changed from 1 Dec 2023 to 31 Dec 2024.
- 02 Apr 2024 Planned primary completion date changed from 1 Jul 2023 to 31 Dec 2024.
- 29 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.